Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Moonshot Antibodies in Stage IV Cancer
NCT07783620Phase 1Not yet recruiting
- Sponsor
- Centre hospitalier de l’Université de Montréal
- Start
- Dec 2026
- Primary completion
- Dec 2029
01
Overview
Phase 1, open-label, single-arm trial of Moonshot antibodies in cancer, sponsored by Centre hospitalier de l’Université de Montréal. Primary endpoint: Safety at 6 months. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
Moonshot antibodies
03
Conditions
cancer
Beyond the preview
Go deeper on NCT07783620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07783620.